Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications

• MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912-1934.
   PubMed Web of Science ®Google Scholar
• KLEBL BM, MULLER G: Second-generation kinase inhibitors. Expert Opin. Ther. Targets (2005) 9(5):975-993.
   PubMed Web of Science ®Google Scholar
• COOPER CS, PARK M, BLAIR DG et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 311:29-33.
   PubMed Web of Science ®Google Scholar
• PARK M, DEAN M, COOPER CS et al.: Mechanism of met oncogene activation. Cell (1986) 45:895-904.
   PubMed Web of Science ®Google Scholar
• LOKKER NA, MARK MR, LUIS EA et al.: Structure-function analysis of hepatocyte growth factor: identificatin of varians that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. (1992) 11:2503-2510.
   PubMed Web of Science ®Google Scholar
• VIGNA E, GRAMAGLIA D, LONGATI P, BARDELLI A, COMOGLIO PM: Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-Met. Oncogene (1999) 18:4275-4281.
   PubMedGoogle Scholar
• MAULIK G, SHRIKHANDE A, KIJIMA T, MA PC, MORRISON PT, SALGIA R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. (2002) 13:41-59.
   PubMed Web of Science ®Google Scholar
• MA PC, MAULIK G, CHRISTENSEN J, SALGIA R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis. Rev. (2003) 22:309-325.
   PubMed Web of Science ®Google Scholar
• JEFFERS M, SCHMIDT L, NAKAIGAWA N et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA (1997) 94:11445-11450.
   PubMed Web of Science ®Google Scholar
• BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VANDE WOUDE GF: Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. (2003) 4:915-925.
   PubMed Web of Science ®Google Scholar
• KANKURI E, CHOLUJOVA D, COMAJOVA M, VAHERI A, BIZIK J: Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res. (2005) 65:9914-9922.
   PubMed Web of Science ®Google Scholar
• BOCCACCIO C, COMOGLIO PM: Invasive growth: a Met-driven generic programme for cancer and stem cells. Nat. Rev. Cancer (2006) 6:637-645.
   PubMed Web of Science ®Google Scholar
• KUCIA M, RECA R, MIEKUS K et al.: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanism: pivotal role of the SDF-1-CXCR4 axis. Stem Cells (2005) 23:879-894.
   PubMed Web of Science ®Google Scholar
• OTSUKA T, JAKUBCZAK J, VIEIRA W et al.: Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell Biol. (2000) 20:2055-2065.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO K, NAKAMURA T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Gann. Monograph Cancer Res. (2004) 52:125-139.
   Google Scholar
• BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. (2006) 66(3):1721-1729
   PubMed Web of Science ®Google Scholar
• BARDELLI A, LONGATI P, WILLIAMS TA, BENVENUTI S, COMOGLIO PM: A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J. Biol. Chem. (1999) 274:29274-29281.
   PubMedGoogle Scholar
• MOROTTI A, MILA S, ACCORNERO P, TAGLIABUE E, PONZETTO C: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene (2002) 20:1692-1703.
   Google Scholar
• SCHIERING N, KNAPP S, MARCONI M et al.: Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. USA (2003) 100:12654-12659.
   PubMed Web of Science ®Google Scholar
• NOBEL MEM, ENDICOTT JA, JOHNSON LN: Protein kinase inhibitors: insights into drug design from structure. Science (2004) 303:1800-1805.
   PubMedGoogle Scholar
• SUN L, LIANG C, SHIRAZIAN S et al.: Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. (2003) 46:1116-1119.
   PubMed Web of Science ®Google Scholar
• WANG X, LE P, LIANG C et al.: Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol. Cancer Ther. (2003) 2:1085-1092.
   PubMed Web of Science ®Google Scholar
• BERTHOU S, AEBERSOLD DM, SCHMIDT LS et al.: The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene (2004) 23:5387-5393.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN JG, SCHRECK R, BURROWS J et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo. Cancer Res. (2003) 63(21):7345-7355.
   PubMed Web of Science ®Google Scholar
• HOV H, UTNE HOLT R, BAADE RØ T et al.: A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhension of myeloma cells. Clin. Cancer Res. (2004) 10:6686-6694.
   PubMedGoogle Scholar
• SMOLEN GA, SORDELLA R, MUIR B et al.: Amplification of Met may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA (2006) 103:2316-2321.
   PubMed Web of Science ®Google Scholar
• CUI J: Discovery and development of potent and highly selective c-Met/HGFR inhibitors, 2nd RSC-SCI Symposium on Kinase Inhibitor Design, Protein Kinase 2007 – More Signalling Success, NV. Organon, Oss, The Netherlands (14 – 15 May 2007).
   Google Scholar
• ZOU HY, LI Q, LEE JH et al.: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. (2007) 67:4408-4417.
   PubMed Web of Science ®Google Scholar
• PAN BS, CHENARD M, DAVIS LJ: In vitro and in vivo anti-tumor activities of a novel c-Met kinase inhibitor. 98th Annual Meeting for America Association for Cancer Research (AACR). Los Angeles, USA (12 – 18 April 2007):A2368.
   Google Scholar
• KUBO K, OHYAMA S, SHIMIZU T et al.: Synthesis and structure–activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg. Med. Chem. (2003) 11:5117-5133.
   PubMedGoogle Scholar
• KUBO K, SHIMIZU T, OHYAMA S et al.: Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N′-{4-(4-quinolyloxy)phenyl}ureas. J. Med. Chem. (2005) 48:1359-1366.
   PubMed Web of Science ®Google Scholar
• LURUSSO P, APPLEMAN L, HEATH E et al.: A Phase I study of a novel spectrum kinase inhibitor (SSKI), XL880, administrated orally in patients with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Philadelphia, USA (14 – 18 November 2005):A245.
   Google Scholar
• BELLON S, KAPLAN-LEFKO P, YANG Y et al.: c-Met inhibitors with novel binding mode show activity against several HPRCC-related mutations. 98th Annual Meeting for America Association for Cancer Research (AACR). Los Angeles, USA (12 – 18 April 2007):A3162.
   Google Scholar
• MUNSHI N, JEAY S, HILL J et al.: ARQ 197, a highly selective small molecule inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells. 98th Annual Meeting for America Association for Cancer Research (AACR). Los Angeles, USA (12 – 18 April 2007):A2367.
   Google Scholar
• JEAY S, MUNSHI N, HILL J et al.: ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. 98th Annual Meeting for America Association for Cancer Research (AACR). Los Angeles, USA (12 – 18 April 2007):A2369.
   Google Scholar
• LI Y, CHEN D, ZHOU W et al.: Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models. 98th Annual Meeting for America Association for Cancer Research (AACR). Los Angeles, USA (12 – 18 April 2007):A2216.
   Google Scholar
• PERUZZI B, BOTTARO DP: Targeting the c-Met signaling pathway in cancer. Clin. Cancer Res. (2006) 12(12):3657-3660.
   PubMed Web of Science ®Google Scholar
• EDER JP: The hepatocyte growth factor and c-Met (HGF/Met) axis as a target in cancer therapy. The 3rd Annual Symposium on The Future of Lung Cancer: A. Translational Focus. Washington DC, USA (1 – 2 December 2006).
   Google Scholar
• KURZROCK R, CAMACHO L, HONG D et al.: A Phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Prague, Czech Republic (7 – 10 November 2006):A405.
   Google Scholar
• ROSEN L, GARCIA A, MULAY M et al.: A Phase I dose escalation study of ARQ 197, a selective inhibitor of the cMet receptor in patients with metastatic solid tumors. 18th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’. Prague, Czech Republic (7 – 10 November 2006):A651.
   Google Scholar
• DANCEY J, SAUSVILLE EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. (2003) 2:298-313.
   Google Scholar
• KOBAYASHI S, BOGGON TJ, DAYARAM T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2005) 352:789-792.
   Google Scholar
• O'REILLY MS: Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin. Cancer Res. (2002) 8(11):3309-3310.
   PubMed Web of Science ®Google Scholar
• ENGELMAN JA, ZEJNULLAHU K, MITSUDOMI T et al.: MET amplication leads to Gefitinib resistance in lung cancer by activating ERBB signaling. Science (2007) 316:1039-1043.
   PubMed Web of Science ®Google Scholar
• BARANDA J, WILLIAMSON S: The new paradigm in the treatment of colorectal cancer: are we hitting the right targets? Expert Opin. Investig. Drugs (2007) 16:311-324.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ: Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. (2004) 91:1-30.
   PubMed Web of Science ®Google Scholar

Patents

• SUGEN/PFIZER: WO0255517 (2002).
   Google Scholar
• SUGEN/PFIZER: WO0296361 (2002).
   Google Scholar
• SUGEN/PFIZERR: WO2002096321 (2002).
   Google Scholar
• PFIZER: WO2004041762 (2004).
   Google Scholar
• PFIZER: WO2004076412 (2004).
   Google Scholar
• PFIZER: WO2005004607 (2005).
   Google Scholar
• PFIZER: WO2005004808 (2005).
   Google Scholar
• PFIZER: WO2005005378 (2005).
   Google Scholar
• PFIZER: WO2005121125 (2005).
   Google Scholar
• PFIZER: WO2006021881 (2006).
   Google Scholar
• PFIZER: WO2006021886 (2006).
   Google Scholar
• JOHNSON & JOHNSON: WO2006101937 (2006).
   Google Scholar
• HOFFMANN-LA ROCHE: WO2003087026 (2003).
   Google Scholar
• HOFFMANN-LA ROCHE: WO2005040345 (2005).
   Google Scholar
• NOVARTIS: WO2003097641 (2003).
   Google Scholar
• VERTEX: WO2005016920 (2005).
   Google Scholar
• VERTEX: WO2005028475 (2005).
   Google Scholar
• MERCK: WO2007002258 (2007).
   Google Scholar
• MERCK: WO2007050380 (2007).
   Google Scholar
• MERCK: WO2007050401 (2007).
   Google Scholar
• KIRIN: WO9717329 (1997).
   Google Scholar
• KIRIN: WO2003000660 (2003).
   Google Scholar
• EISAI: WO2005082855 (2005).
   Google Scholar
• EISAI: WO2005082854 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB: WO2005116028 (2005).
   Google Scholar
• BRISTOL-MYERS SQUIBB: WO2005117867 (2005).
   Google Scholar
• EXELIXIS: WO2005030140 (2005).
   Google Scholar
• EXELIXIS: WO2006014325 (2006).
   Google Scholar
• EXELIXIS: WO2006108059 (2006).
   Google Scholar
• AMGEN: WO2006060318 (2006).
   Google Scholar
• AMGEN: WO2006116713 (2006).
   Google Scholar
• BRISTOL-MYERS SQUIBB: WO2007033196 (2007).
   Google Scholar
• METHYLGENE: WO2006010264 (2006).
   Google Scholar
• METHYLGENE: US2007004675 (2007).
   Google Scholar
• KIRIN: WO2006104161 (2006).
   Google Scholar
• EISAI: WO2007023768 (2007).
   Google Scholar
• AMGEN: WO2007005668 (2007).
   Google Scholar
• ARQULE: WO2006086484 (2006).
   Google Scholar

Website

• http://www.amgen.com/science/pipe_AMG102.html Information on AMG-102, a fully human monoclonal antibody that targets the action of HGF. Phase II studies of AMG-102 as a potential cancer therapeutic are ongoing (Accessed 16 August 2007).
   Google Scholar